Last reviewed · How we verify
JMKX001899
JMKX001899 is a small molecule that targets the S1P1 receptor.
JMKX001899 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.
At a glance
| Generic name | JMKX001899 |
|---|---|
| Sponsor | Jemincare |
| Drug class | S1P1 receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By binding to the S1P1 receptor, JMKX001899 modulates sphingosine-1-phosphate signaling, which plays a crucial role in various cellular processes, including immune cell trafficking and lymphocyte egress from lymphoid organs.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Nausea
- Headache
- Diarrhea
- Fatigue
Key clinical trials
- Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC (PHASE3)
- A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation (PHASE1)
- To Assess the Effects of Single Dose of JMKX001899 on QTc Interval in Healthy Subjects (PHASE1)
- Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- JMKX001899 CI brief — competitive landscape report
- JMKX001899 updates RSS · CI watch RSS
- Jemincare portfolio CI